Schafranski Marcelo Derbli, Malucelli Tiago, Machado Fabíola, Takeshi Hélcio, Kaiber Flávia, Schmidt Carolina, Harth Fabielle
Department of Rheumatology, Santa Casa de Misericórdia, Rua Carlos Osternack, 111, 84010-120, Ponta Grossa, PR, Brazil.
Clin Rheumatol. 2009 Jul;28(7):853-5. doi: 10.1007/s10067-009-1137-8. Epub 2009 Mar 5.
Fibromyalgia is a disorder characterized by chronic widespread pain. In this study, we investigated the effect of intravenous infusions of lidocaine in pain and quality of life of patients with fibromyalgia. Twenty-three consecutive patients were included in the study, which consisted on five sequential intravenous 2% lidocaine infusions with rising dosages (2-5 mg/kg, days 1-5). Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire, and a visual analog scale (VAS) for pain were applied before the first lidocaine infusion, immediately after the fifth infusion and 30 days after the fifth infusion. A significant improvement was observed in the FIQ scores after the fifth infusion (73.52 +/- 16.56 vs 63.29 +/- 21.21, p = 0.02), which was maintained after 30 days (73.52 +/- 16.56 vs 63.85 +/- 24.59, p = 0.04). Similar results were seen concerning the VAS: 8.19 +/- 1.76 vs 6.84 +/- 2.44, p = 0.01 and 8.19 +/- 1.76 vs 7.17 +/- 2.35, p = 0.05, respectively. Intravenous lidocaine infusions are safe and effective in the management of fibromyalgia.
纤维肌痛是一种以慢性广泛性疼痛为特征的疾病。在本研究中，我们调查了静脉输注利多卡因对纤维肌痛患者疼痛及生活质量的影响。23例连续患者纳入本研究，研究包括连续5次静脉输注2%利多卡因，剂量递增（2 - 5mg/kg，第1 - 5天）。在首次输注利多卡因前、第5次输注后即刻以及第5次输注后30天，应用纤维肌痛影响问卷（FIQ）、健康评估问卷以及疼痛视觉模拟量表（VAS）。第5次输注后FIQ评分显著改善（73.52±16.56对63.29±21.21，p = 0.02），30天后仍维持改善（73.52±16.56对63.85±24.59，p = 0.04）。VAS也有类似结果：分别为8.19±1.76对6.84±2.44，p = 0.01以及8.19±1.76对7.17±2.35，p = 0.05。静脉输注利多卡因在纤维肌痛的治疗中安全有效。
